<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079217</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-4007</org_study_id>
    <nct_id>NCT05079217</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19</brief_title>
  <official_title>A Randomized, Double-Blinded Clinical Trial to Evaluate Additional Dose of Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine in Healthy Individuals Previously Vaccinated With CoronaVac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated&#xD;
      vaccine manufactured by manufactured by Sinovac Research &amp; Development Co., Ltd. The purpose&#xD;
      of this study is to evaluate the safety and immunogenicity of booster vaccination with&#xD;
      high-dosage SARS-CoV-2 vaccine in populations who have received two-dose Coronavac with 2nd&#xD;
      dose vaccinated more than 6 month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated&#xD;
      vaccine .The purpose of this study is to evaluate the safety and immunogenicity of booster&#xD;
      vaccination with high-dosage SARS-CoV-2 vaccine in populations who have received two-dose&#xD;
      Coronavac with 2nd dose vaccinated more than 6 month.A total of 1200 subjects who have&#xD;
      received two-dose Coronavac with 2nd dose vaccinated more than 6 month will be enrolled.All&#xD;
      of subjects will be randomly divided into two groups in a 1:1 ratio .Subjects in experimental&#xD;
      group will receive high-dosage SARS-CoV-2 inactivated vaccine.Subjects in control group will&#xD;
      receive medium-dosage SARS-CoV-2 inactivated vaccine .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity index-GMT of neutralizing antibodies（CZ02 strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>GMT of neutralizing antibodies（CZ02 strain） 28 days after booster vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seropositive rate of neutralizing antibodies（CZ02 strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>The seropositive rate of neutralizing antibodies（CZ02 strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seroconversion rate of neutralizing antibodies（CZ02 strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibodies（CZ02 strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-GMI of neutralizing antibodies（CZ02 strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>GMI of neutralizing antibodies（CZ02 strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seropositive rate of neutralizing antibodies（Delta Strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibodies（Delta Strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-seroconversion rate of neutralizing antibodies（Delta Strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibodies（Delta Strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity index-GMI of neutralizing antibodies（Delta Strain）</measure>
    <time_frame>Day 28 after booster vaccination</time_frame>
    <description>GMI of neutralizing antibodies（Delta Strain） 28 days after booster vaccination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity index-the seropositive rate of neutralizing antibodies（CZ02 strain and Delta Strain）</measure>
    <time_frame>6 months after the booster vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibodies（CZ02 strain and Delta Strain） 6 months after the booster vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity index-GMT of neutralizing antibodies（CZ02 strain and Delta Strain）</measure>
    <time_frame>6 months after the booster vaccination</time_frame>
    <description>GMI of neutralizing antibodies（CZ02 strain and Delta Strain） 6 months after the booster vaccination</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-dosage SARS-CoV-2 vaccine</intervention_name>
    <description>SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Medium-dosage SARS-CoV-2 vaccine</intervention_name>
    <description>SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18-59;&#xD;
&#xD;
          -  Proven legal identity;&#xD;
&#xD;
          -  The subjects can understand and voluntarily sign the informed consent form and be&#xD;
             willing to complete the study in accordance with the study plan;&#xD;
&#xD;
          -  Have received two doses of inactivated SARS-CoV-2 vaccine(CoronaVac) manufactured by&#xD;
             Sinovac Research &amp; Development Co., Ltd at an interval of 21 to 35 days and is&#xD;
             currently 6-8 months (180 to 240 days) after the second dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of SARS-CoV-2 infection(laboratory confirmed);&#xD;
&#xD;
          -  Have received three and more doses of inactivated SARS-CoV-2 vaccine;&#xD;
&#xD;
          -  Severe adverse reactions, such as urticaria, dyspnea, and angioneurotic edema ,&#xD;
             occurred during the primary immunization;&#xD;
&#xD;
          -  Autoimmune disease such as systemic lupus erythematosus or immunodeficiency /&#xD;
             immunosuppression such as AIDS, post-transplant;&#xD;
&#xD;
          -  Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes&#xD;
             that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors,&#xD;
             blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis&#xD;
             superficial corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Receipt of blood products within in the past 3 months;&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days;&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Acute diseases or acute exacerbation of chronic diseases within 7 days prior to&#xD;
             booster vaccination;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0°C;&#xD;
&#xD;
          -  Already pregnant or are breastfeeding, planning to get pregnant within 1months&#xD;
             (according to subjects' self-report and urine pregnancy test results);&#xD;
&#xD;
          -  Participated in other clinical trials prior to enrollment and during the follow-up&#xD;
             period, or planned to participate in other clinical trials during the clinical trial&#xD;
             period;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongxing Pan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongxing Pan, Master</last_name>
    <phone>18118996996</phone>
    <email>panhongxing@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinqi City Center for Disease Control and Prevention</name>
      <address>
        <city>Xinqi</city>
        <state>Jiangsu</state>
        <zip>221400</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guang wei Sun</last_name>
      <phone>15262178006</phone>
      <email>2714887832@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

